The‐first‐in‐man randomized trial of a β3AR agonist in chronic HF (BEAT‐HF) was recently conducted in 70 patients with NYHA Classes II and III HF and LVEF <40% at screening echocardiography.49 Patients received mirabegron or placebo for 6 months as add‐on to optimized standard therapy. This evidence concerns the gene ADRB3 and hydrops fetalis.